Tlr9 modulators for treating cancer
AssigneeIdera Pharmaceuticals, Inc.
InventorsCara HAYMAKER, Chantale BERNATCHEZ, Adi DIAB, Srinivas CHUNDURU
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating cancer in patients having low expression of MHC Class I genes, and in patients having increased serum levels of PD-L2 by administration of a TLR9 agonist.
Claims32
A method for treating a tumor in a patient having low tumor expression of MHC Class I genes, the method comprising:
- intratumoral administration of a TLR 9 agonist.
4-5. (canceled)
7-8. (canceled)
12-13. (canceled)
(canceled)
17-23. (canceled)
25-26. (canceled)
A method for treating a tumor in a patient comprising:
- (a) determining MHC Class I gene expression in a tumor sample and
- (b) administering a TLR9 agonist if said gene expression is present in less than 50% of the tumor cells.
30-52. (canceled)
A method for treating a tumor in a patient having increased serum PD-L2 levels, the method comprising:
- (a) determining the level of PD-L2 levels in said patient;
- and
- (b) administering a TLR9 agonist if said PD-L2 levels in said patient are increased as compared with a control level of PD-L2.
55-58. (canceled)
61-62. (canceled)
64-66. (canceled)
68-78. (canceled)
(canceled)
Dependencies are inferred from the claim text.